Clinical heterogeneity in patients with Non-Alcoholic Fatty Liver Disease associated Hepatocellular Carcinoma.

INTRODUCTION: The indisputable increase in non-Alcoholic Fatty Liver Disease (NAFLD) prevalence, has consequently led to an increase in Hepatocellular Carcinoma (HCC) and liver-related mortality worldwide. Twenty-five percent of the general population present with various degrees of steatosis and most of them are unaware of their disease until its progression to advanced stages The characteristics of patients with HCC, secondary to NAFLD, are older age, large tumours due to late diagnosis, often without cirrhosis and high prevalence of the metabolic syndrome components, leading to an increased mortality rate. Although the mechanisms of disease remain partially obscure, insulin resistance, oxidative stress, apoptosis, iron overload and excessive local and systemic inflammation are identified as culprits for hepatocarcinogenesis in the presence of NAFLD.

AREA COVERED: In this review, the authors report that there are no uniform guidelines for surveillance and early diagnosis in this patient group. Barcelona Clinic Liver Cancer staging is generally applicable to HCC due to NAFLD and management depends on liver function, tumour characteristics and cardiovascular comorbidity. Evidence suggests that HCC due to NAFLD can be associated with worse survival due to late diagnosis.

EXPERT OPINION: The need for effective early diagnosis and management of NAFLD is urgent, considering the galloping incidence of the obesity and the fact that liver cirrhosis and HCC due to NAFLD will become the first indication for liver transplantation in foreseeable future.